IRCT20190404043159N5 IRCT 2021-12-13 Esfahan University of Medical Sciences Evaluation of the effectiveness of probiotic/prebiotic on the severity of depressive symptoms and irritable bowel syndrome Evaluation of the effectiveness of adding probiotic / prebiotic combination to the usual treatment on the severity of depressive symptoms and irritable bowel syndrome 2021-12-22 anticipated 48 Complete https://irct.ir/trial/60339 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 48 eligible patients are randomly selected. For this, the letter A is written on 24 sheets, and the letter B is written on 24 sheets and each of them is placed in an envelope. Each patient is then asked to choose one of the envelopes. Depending on the selected envelope, the patient is assigned to one of two groups, Blinding description: In order to observe blindness, the drugs are prepared in the same shape and amount before the intervention and are coded and given to the physician. They prescribe them without knowing the type of each drug. Therefore, the patient, the patient, the person recording the clinical and baseline information of the patients as well as the statistical analyst will not be aware of the type of intervention. 3 Irritable bowel syndrome. Intervention 1: Intervention group 1: For patients in this group, in addition to the usual treatment, the probiotic/prebiotic combination of familact 2 Plus (which contains eight bacterial strains and the prebiotic fructooligosaccharide) is given as one capsule daily for 12 weeks. Intervention 2: Control group: For patients in this group, only the usual treatment is used and capsules containing corn starch (as a placebo) similar to the intervention group will be prescribed. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information